H.C. Wainwright Reiterates Buy Rating on Talphera (TLPH)

Thu, 13 Aug 2026 07:03:57 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $3.00 price target on Talphera (NASDAQ: TLPH).

The analyst commented: "Talphera’s 2Q26 update supports our positive view on the stock with NEPHRO enrollment moving along well and the commercial opportunity looking larger and more concentrated than we had previously assumed. The study is now 75% enrolled, all targeted sites are activated following the site realignment, and management continues to expect enrollment completion in 2026, with topline data roughly four to five weeks thereafter. More importantly, blinded operational observations suggest the titration protocol is behaving as designed, while the first independent safety

Form S-8 TALPHERA, INC.

Wed, 12 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26914084.html

Form S-8 TALPHERA, INC.

Wed, 12 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26914084.html

Talphera (TLPH) Reports In-Line Q2 EPS

Wed, 12 Aug 2026 16:27:22 -0400

Talphera (NASDAQ: TLPH) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Talphera (TLPH) click here.

Form 10-Q TALPHERA, INC. For: Jun 30

Wed, 12 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26912959.html

Form 10-Q TALPHERA, INC. For: Jun 30

Wed, 12 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26912959.html

Form 8-K TALPHERA, INC. For: Aug 12

Wed, 12 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260812/26912872.html

Form 8-K TALPHERA, INC. For: Aug 12

Wed, 12 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260812/26912872.html

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines

Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion

Cash and investments of $17.1 million at June 30, 2026

Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET

SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ --

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines

Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion

Cash and investments of $17.1 million at June 30, 2026

Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET

SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ --

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines

Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion

Cash and investments of $17.1 million at June 30, 2026

Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET

SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ --

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines

Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion

Cash and investments of $17.1 million at June 30, 2026

Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET

SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ --

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines

Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion

Cash and investments of $17.1 million at June 30, 2026

Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET

SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ --

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines

Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion

Cash and investments of $17.1 million at June 30, 2026

Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET

SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ --

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines

Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion

Cash and investments of $17.1 million at June 30, 2026

Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET

SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ --

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 12 Aug 2026 16:05:00 -0400

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year

Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines

Updated market research indicates an estimated 200,000 annual U.S. CRRT procedures, a 21% increase over prior estimates; investor event planned as enrollment nears completion

Cash and investments of $17.1 million at June 30, 2026

Conference call and webcast to be held on Wednesday August 12, 2026 at 4:30 pm ET

SAN MATEO, Calif., Aug. 12, 2026 /PRNewswire/ --

Form SCHEDULE 13G/A TALPHERA, INC. Filed by: Rosalind Advisors, Inc.

Wed, 12 Aug 2026 15:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26912211.html

Form SCHEDULE 13G/A TALPHERA, INC. Filed by: Rosalind Advisors, Inc.

Wed, 12 Aug 2026 15:04:00 -0400

si-local-file:///var/storage/secattach/20260812/26912211.html

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Wed, 05 Aug 2026 16:05:00 -0400

SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the second quarter ended June 30, 2026 and recent business progress.

Conference Call and Webcast Information

Date: Wednesday, August 12, 2026 at 4:30 PM ET/1:30 PM PT
Participant Dial-in (
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Wed, 05 Aug 2026 16:05:00 -0400
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the second quarter ended June 30, 2026 and recent business progress.
Conference Call and Webcast Information
- Date: Wednesday, August 12, 2026 at 4:30 PM ET/1:30 PM PT
- Participant Dial-in (
  
  Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
  
  Wed, 05 Aug 2026 16:05:00 -0400
  
  SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the second quarter ended June 30, 2026 and recent business progress.
  Conference Call and Webcast Information
  Date: Wednesday, August 12, 2026 at 4:30 PM ET/1:30 PM PT
  Participant Dial-in (
  
  Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
  
  Wed, 05 Aug 2026 16:05:00 -0400
  
  SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the second quarter ended June 30, 2026 and recent business progress.
  Conference Call and Webcast Information
  Date: Wednesday, August 12, 2026 at 4:30 PM ET/1:30 PM PT
  Participant Dial-in (
  
  Form 4 TALPHERA, INC. For: Jun 22 Filed by: WAN MARK A
  
  Wed, 24 Jun 2026 17:16:00 -0400
  si-local-file:///var/storage/secattach/20260624/26686467.html
  
  Form 4 TALPHERA, INC. For: Jun 22 Filed by: WAN MARK A
  
  Wed, 24 Jun 2026 17:16:00 -0400
  si-local-file:///var/storage/secattach/20260624/26686467.html
  
  Form 4 TALPHERA, INC. For: Jun 22 Filed by: Todisco Joseph
  
  Wed, 24 Jun 2026 17:15:00 -0400
  si-local-file:///var/storage/secattach/20260624/26686452.html

StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Talphera (TLPH)

Form S-8 TALPHERA, INC.

Form S-8 TALPHERA, INC.

Talphera (TLPH) Reports In-Line Q2 EPS

Form 10-Q TALPHERA, INC. For: Jun 30

Form 10-Q TALPHERA, INC. For: Jun 30

Form 8-K TALPHERA, INC. For: Aug 12

Form 8-K TALPHERA, INC. For: Aug 12

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Form SCHEDULE 13G/A TALPHERA, INC. Filed by: Rosalind Advisors, Inc.

Form SCHEDULE 13G/A TALPHERA, INC. Filed by: Rosalind Advisors, Inc.

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Form 4 TALPHERA, INC. For: Jun 22 Filed by: WAN MARK A

Form 4 TALPHERA, INC. For: Jun 22 Filed by: WAN MARK A

Form 4 TALPHERA, INC. For: Jun 22 Filed by: Todisco Joseph